Palisade Bio Financials - Benzinga

Palisade Bio Inc

PALINASDAQ

Trade with Public

Trade with Public

$1.45

-0.12-7.64%

近くで: Sep 25, 5:00 PM EST

$1.49

0.03882.68%

時間外: 7:59 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較株式レポート

Palisade Bio Financials

Palisade Bio (PALI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The

Benzinga Newsdesk

PRO
Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 89.36 percent increase over losses of $(0.47) per share from the

Benzinga Newsdesk

Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December

Avi Kapoor

PRO
Palisade Bio Q3 EPS $(0.38) Misses $(0.27) Estimate

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.27) by 39.19 percent. This is a 83.62 percent increase over losses of $(2.32) per share from

Benzinga Newsdesk

PRO
Palisade Bio Q1 EPS $(0.47) Beats $(0.70) Estimate

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.70) by 32.86 percent. This is a 89.76 percent increase over losses of $(4.59) per share from the

Benzinga Newsdesk

Nasdaq Down 50 Points; US Initial Jobless Claims Rise

Avi Kapoor

© 2026 Benzinga | All Rights Reserved